Details

Odnosi z javnostmi v neprofitnih nevladnih organizacij : primer: program pravična trgovina in projekt ogledalo vladi 2006 Slovenske fondacije za trajnostni razvoj, Umanotere
ID Vreš, Janja (Author), ID Škerlep, Andrej (Mentor) More about this mentor... This link opens in a new window

URLURL - Presentation file, Visit http://dk.fdv.uni-lj.si/diplomska/pdfs/Vres-Janja.PDF This link opens in a new window

Language:Slovenian
Work type:Undergraduate thesis
Typology:2.11 - Undergraduate Thesis
Organization:FDV - Faculty of Social Sciences
Place of publishing:Ljubljana
Publisher:[J. Vreš]
Year:2007
Number of pages:92 f.
PID:20.500.12556/RUL-9249 This link opens in a new window
UDC:341.215.2(043)
COBISS.SI-ID:26405213 This link opens in a new window
Publication date in RUL:11.07.2014
Views:1755
Downloads:132
Metadata:XML DC-XML DC-RDF
:
VREŠ, Janja, 2007, Odnosi z javnostmi v neprofitnih nevladnih organizacij : primer: program pravična trgovina in projekt ogledalo vladi 2006 Slovenske fondacije za trajnostni razvoj, Umanotere [online]. Bachelor’s thesis. Ljubljana : J. Vreš. [Accessed 17 April 2025]. Retrieved from: http://dk.fdv.uni-lj.si/diplomska/pdfs/Vres-Janja.PDF
Copy citation
Share:Bookmark and Share

Similar documents

Similar works from RUL:
  1. Systematic review of observational studies evaluating the effectiveness and safety of immune checkpoint inhibitors in patients with metastatic non-small-cell lung cancer
  2. Effectivness and safety of immunotherapy in patients with advanced non-small cell lung cancer in second line treatment at the University Clinic Golnik
  3. Description of adverse event of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer treated at the University Clinic Golnik
  4. ǂThe ǂpotential of immunotherapies in the treatment of lung cancer
  5. Real-world outcomes of immunotherapy with or without chemotherapy in first-line treatment of advanced non-small cell lung cancer
Similar works from other Slovenian collections:
  1. Advances in the therapy with immune-check point inhibitors (ICI) in non-small cell lung cancer (NSCLC) in 2022
  2. Trans-esophageal endobronchial ultrasound-guided needle aspiration (EUS-B-NA)
  3. ǂThe ǂrole of immune checkpoint inhibitors in the treatment of cancer of unknown origin
  4. Febrile neutropenia and grade 3/4 neutropenia in daily practice of adjuvant chemotherapy for non-small-cell lung cancer
  5. Neurological adverse events of immune checkpoint inhibitors

Back